Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial

Anirban P. Mitra, Vikram M. Narayan, Sharada Mokkapati, Tanner Miest, Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella, Ashish M. Kamat, Trinity J. Bivalacqua, Jeffrey S. Montgomery, Seth P. Lerner, J. Erik Busby, Michael Poch, Paul L. Crispen, Gary D. Steinberg, Anne K. Schuckman, Tracy M. Downs, Robert S. SvatekJoseph Mashni, Brian R. Lane, Thomas J. Guzzo, Gennady Bratslavsky, Lawrence I. Karsh, Michael E. Woods, Gordon A. Brown, Daniel Canter, Adam Luchey, Yair Lotan, Tracey Krupski, Brant A. Inman, Michael B. Williams, Michael S. Cookson, Kirk A. Keegan, Gerald L. Andriole, Alexander I. Sankin, Alan Boyd, Michael A. O'Donnell, Richard Philipson, Seppo Ylä-Herttuala, David Sawutz, Nigel R. Parker, David J. McConkey, Colin P.N. Dinney

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences